Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.46 |
| ▸ | MET | P08581 | 1/20 | 0.46 |
| ▸ | GSK3B | P49841 | 1/20 | 0.46 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.46 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.46 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | ELANE | P08246 | 2/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2082070 | 0.88 | NR4A2 (0.52) | NR4A2L3MBTL1CHEK1METGSK3B | |
| SCHEMBL31264481 | 0.84 | SMN1; SMN2 (0.50) | L3MBTL1ALDH1A1GAATSHRHTT | |
| SCHEMBL1096821 | 0.84 | SMN1; SMN2 (0.50) | L3MBTL1ALDH1A1GAATSHRHTT | |
| SCHEMBL30701731 | 0.83 | CA12 (0.53) | NR4A2CHEK1METGSK3BLIMK1 | |
| SCHEMBL1324146 | 0.83 | CA12 (0.53) | NR4A2CHEK1METGSK3BLIMK1 | |
| SCHEMBL10952907 | 0.83 | NR4A2 (0.51) | NR4A2L3MBTL1CHEK1METGSK3B | |
| SCHEMBL497770 | 0.82 | CYP2A6 (0.44) | NR4A2DYRK1AALDH1A1TSHRHTT | |
| SCHEMBL8584892 | 0.82 | CYP2A6 (0.45) | NR4A2L3MBTL1CHEK1METGSK3B | |
| SCHEMBL2811677 | 0.81 | KDM4E (0.49) | NR4A2L3MBTL1CHEK1METGSK3B | |
| Hydrochloric Acid SCHEMBL30701699 | 0.81 | CA12 (0.51) | NR4A2CHEK1METGSK3BLIMK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1984360-B1 | Compounds and methods for modulating FX-receptors | LILLY CO ELI (US) | 2014-01-15 | — | — | EP | disclosed |
| US-8106077-B2 | Compounds and methods for modulating FXR | ELI LILLY AND COMPANY (US) | 2012-01-31 | — | — | US | disclosed |
| US-7863302-B2 | Compounds and methods for modulating FX-receptors | ELI LILLY AND COMPANY (US) | 2011-01-04 | — | — | US | disclosed |
| US-7846960-B2 | FXR agonists | ELI LILLY AND COMPANY (US) | 2010-12-07 | — | — | US | disclosed |
| EP-2029547-B1 | FXR AGONISTS | LILLY CO ELI (US) | 2010-04-28 | — | — | EP | disclosed |
| EP-2029558-B1 | COMPOUNDS AND METHODS FOR MODULATING FXR | LILLY CO ELI (US) | 2010-03-10 | — | — | EP | disclosed |
| US-20090270460-A1 | FXR AGONISTS | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR COLLATERAL AGENT | 2009-10-29 | — | — | US | disclosed |
| US-20090093524-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR COLLATERAL AGENT | 2009-04-09 | — | — | US | disclosed |
| EP-2029547-A1 | FXR AGONISTS | ELI LILLY AND COMPANY (US) | 2009-03-04 | — | — | EP | disclosed |
| EP-2029558-A2 | COMPOUNDS AND METHODS FOR MODULATING FXR | ELI LILLY AND COMPANY (US) | 2009-03-04 | — | — | EP | disclosed |
| US-20080306125-A1 | Compounds and Methods for Modulating Fx-Receptors | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR COLLATERAL AGENT | 2008-12-11 | — | — | US | disclosed |
| EP-1984360-A2 | COMPOUNDS AND METHODS FOR MODULATING FX-RECEPTORS | Eli Lilly & Company (US) | 2008-10-29 | — | — | EP | disclosed |
| WO-2007140183-A1 | FXR AGONISTS | ELI LILLY AND COMPANY (US) | 2007-12-06 | — | — | WO | disclosed |
| WO-2007140174-A2 | COMPOUNDS AND METHODS FOR MODULATING FXR | ELI LILLY AND COMPANY (US) | 2007-12-06 | — | — | WO | disclosed |
| WO-2007092751-A2 | COMPOUNDS AND METHODS FOR MODULATING FX-RECEPTORS | ELI LILLY AND COMPANY (US) | 2007-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270460-A1 | FXR AGONISTS | NR1H4, SLC10A1, GPBAR1 | NR4A2 263/4885L3MBTL1 4304/4885CHEK1 4295/4885 |
| US-20080306125-A1 | Compounds and Methods for Modulating Fx-Receptors | F2R, TBXA2R, PTAFR | NR4A2 1079/4885L3MBTL1 4833/4885CHEK1 4616/4885 |
| US-20090093524-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | NR1H4, SLC10A1, FXR1 | NR4A2 529/4885L3MBTL1 4726/4885CHEK1 4487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.